History

Syntab has been initiated and seed financed in 2010 by co-founder Dr. Andre Koltermann (former CEO and founder of Direvo Biotech AG and former Executive Vice President at Süd-Chemie AG and Clariant AG), a serial biotech entrepreneur, and Prof. Christian Becker (Head of Institute for Biological Chemistry, University of Vienna), an in-depth connoisseur of peptide chemistry and peptide possibilities.

Syntab Therapeutics is supported by public funding programs, including those of the German Federal Ministry of Research, Technology and Space (BMFTR), the State of North Rhine-Westphalia, and its EFRE-funded Life Sciences.NRW program.

Over the years, the company has also attracted a group of experienced biotech investors, reflecting their strong confidence in Syntab’s potential.